{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:23:12Z","timestamp":1791379392987,"version":"4.3.2"},"reference-count":19,"publisher":"MedWorks Media","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Introduction\nSecond-Generation Antipsychotics (SGAs) are widely used for treating psychiatric disorders due to their favorable side effect profile compared to First-Generation Antipsychotics (FGAs). However, SGAs are associated with significant metabolic side effects. This study aims to explore the sociodemographic and health differences between individuals using SGAs and those not using them.\nMethods\nA comparative cross-sectional study was conducted with 148 participants, including 102 SGA users and 46 non-users. Data were collected from patients and medical records, encompassing sociodemographic factors and health variables including diabetes mellitus, hypertension, cardiovascular disease, hyperlipidemia, waist circumference, fasting blood glucose, cholesterol, triglycerides, HDL, LDL, and BMI. Statistical analyses included chi-square and Fisher\u2019s exact tests to compare the two groups.\nResults\nSGA users had higher rates of overweight and obesity compared to non-users (p = 0.000), with 30.4% overweight and 29.4% obese among SGA users versus 21.7% overweight and 4.3% obese among non-users. A higher prevalence of cardiovascular disease was observed in SGA users (11.8% vs. 2.2%, p = 0.076). Although not statistically significant, trends indicated higher rates of diabetes mellitus and hyperlipidemia in non-users (30.4% vs. 18.6%, p = 0.110 and 7% vs. 0%, p = 0.083, respectively).\nConclusion\nThis study highlights significant differences in BMI and cardiovascular disease prevalence between SGA users and non-users, reinforcing the need for comprehensive metabolic monitoring in patients treated with SGAs. The findings underscore the importance of considering sociodemographic factors in managing the health risks associated with SGA use. Further research with larger sample sizes and longitudinal designs is warranted to better understand these associations and develop targeted interventions.<\/jats:p>","DOI":"10.64719\/pb.4502","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"35-44","source":"Crossref","is-referenced-by-count":1,"title":["Metabolic Syndrome among Patients Taking Atypical Antipsychotics: A Comparative Cross-Sectional Study at Erada and Mental Health Complex in Taif, Saudi Arabia"],"prefix":"10.64719","volume":"54","author":[{"given":"Dhaifallah M","family":"Alhasani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas Ibn","family":"Auf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah R","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17(2):97\u2013107.","DOI":"10.1016\/j.molmed.2010.10.010"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1\u201393.","DOI":"10.2165\/00023210-200519001-00001"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52\u201377.","DOI":"10.1002\/j.2051-5545.2011.tb00014.x"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Thornicroft G. Physical health disparities and mental illness: the scandal of premature mortality. Br J Psychiatry. 2011;199(6):441\u2013442.","DOI":"10.1192\/bjp.bp.111.092718"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment\u2014pharmacological mechanisms. Pharmacol Ther. 2010;125(1):169\u2013179. [Internet] Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725809002149.","DOI":"10.1016\/j.pharmthera.2009.10.010"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes. 2010;17(5):460\u2013466. [Internet] Available from: http:\/\/journals.lww.com\/01266029-201010000-00015.","DOI":"10.1097\/MED.0b013e32833de61c"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia\u2014A randomized double-blind controlled, short-term prospective study. Schizophr Res. 2008;101(1\u20133):266\u2013272. [Internet] Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996408000510.","DOI":"10.1016\/j.schres.2008.01.004"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther. 2005;27(12):1930\u20131941. [Internet] Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291805003176.","DOI":"10.1016\/j.clinthera.2005.12.005"},{"key":"ref9","unstructured":"Baptista T, El-Fakih Y, Uzc\u00e1tegui E, Sandia I, Talamo E, de Baptista EA et al. Drug-induced weight gain, metabolic parameters, and comorbidities in psychiatric patients treated in Venezuela. Clin Drug Investig. 2008;28(4):317\u2013324."},{"key":"ref10","unstructured":"Santini A, Novick D, Haro JM, Bertsch J, Nguyen D, Fagiolini A. The metabolic syndrome in patients with schizophrenia: is it more prevalent than in the general population? A comparative study using matched samples. J Psychopharmacol. 2016;30(1):70\u201377."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2014a systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306\u2013318.","DOI":"10.1093\/schbul\/sbr148"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health. 2006;2:14.","DOI":"10.1186\/1745-0179-2-14"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Bajaj S, Rani V, Choudhary R. Prevalence of metabolic syndrome in patients with schizophrenia. Indian J Endocrinol Metab. 2013;17(4):723\u2013726.","DOI":"10.4103\/2230-8210.113768"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Gautam S, Meena PS. Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. Indian J Psychiatry. 2011;53(2):128\u2013133.","DOI":"10.4103\/0019-5545.82537"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Olfson M, Blanco C, Wang S, Laje G, Correll CU. National trends in the mental health care of children, adolescents, and adults by office-based physicians. JAMA Psychiatry. 2014;71(1):81\u201390.","DOI":"10.1001\/jamapsychiatry.2013.3074"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425\u201348.","DOI":"10.1146\/annurev-clinpsy-032813-153657"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Thornicroft G. Physical health disparities and mental illness: the scandal of premature mortality. Br J Psychiatry. 2011;199(6):441\u2013442.","DOI":"10.1192\/bjp.bp.111.092718"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. 2012;38(1):167\u2013177.","DOI":"10.1093\/schbul\/sbq042"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17(2):97\u2013107.","DOI":"10.1016\/j.molmed.2010.10.010"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:32:49Z","timestamp":1791315169000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/metabolic-syndrome-among-patients-taking-atypical-antipsychotics-a-comparative-cross-sectional-study-at-erada-and-mental-health-complex-in-taif-saudi-arabia\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4502","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}